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INTRODUCTION 
In the past 25 years only modest advancements in glioma treatment have 
been made, with patient prognosis and median survival time following 
diagnosis only increasing from 3 to 7 months. A substantial body of clinical 
and preclinical evidence has suggested a role for aspirin in the treatment of 
cancer with multiple mechanisms of action proposed including COX 2 
inhibition, down regulation of EGFR expression, and NF-κB signaling 
affecting Bcl-2 expression. However, with serious side effects such as stroke 
and gastrointestinal bleeding, aspirin analogues with improved potency and 
side effect profiles are being developed. 
METHOD 
Effects on cell viability following 24 hr incubation of four aspirin derivatives 
(PN508, 517, 526 and 529) were compared to cisplatin, aspirin and di-aspirin 
in four glioma cell lines (U87 MG, SVG P12, GOS – 3, and 1321N1), using 
the PrestoBlue assay, establishing IC50 and examining the time course of 
drug effects. 
 
RESULTS 
All compounds were found to decrease cell viability in a concentration and 
time dependant manner.  Significantly, the analogue PN517 (IC50 2mM) 
showed approximately a twofold increase in potency when compared to 
aspirin (3.7mM) and cisplatin (4.3mM) in U87 cells, with similar increased 
potency in SVG P12 cells. Other analogues demonstrated similar potency to 
aspirin and cisplatin. 
 
CONCLUSION 
These results support the further development and characterization of novel 
NSAID derivatives for the treatment of glioma. 
